Keyphrases
Extracellular Matrix
100%
Hyaluronic Acid
100%
Glioblastoma
100%
Gelatin Hydrogel
100%
Patient-derived
100%
Matrix Signals
100%
Erlotinib
100%
Glioblastoma multiforme
83%
Epidermal Growth Factor Receptor
50%
EGFRvIII
50%
Tumor Microenvironment
33%
Glioblastoma Cells
33%
EGFR mutation
33%
Engineering Approach
16%
Three-dimensional (3D)
16%
Therapeutic Efficacy
16%
Ex Vivo Tissues
16%
Tissue Engineering
16%
Tissue-engineered Constructs
16%
Cell Proliferation
16%
Cell Survival
16%
Cell Signaling
16%
Therapeutic Potential
16%
Poor Response
16%
Phosphorylation State
16%
Receptor Cells
16%
Constitutively Active
16%
Cell Migration
16%
Tyrosine Kinase Inhibitor
16%
Primary Glioblastoma
16%
Phosphatase
16%
Cluster of Differentiation 44 (CD44)
16%
Poor Clinical Outcomes
16%
Tensin Homolog
16%
Acquired Resistance
16%
Metabolic Signaling
16%
Biophysical Signal
16%
Proliferation Pathway
16%
Xenograft Tumor
16%
STAT3 Phosphorylation
16%
Mutation Status
16%
Signaling Pathway Activation
16%
Targeted Inhibitors
16%
Medicine and Dentistry
Extracellular Matrix
100%
Glioblastoma
100%
Gelatin
100%
Restylane
100%
Erlotinib
100%
Epidermal Growth Factor Receptor
45%
Neoplasm
27%
Tumor Microenvironment
18%
Cell Migration
9%
In Vitro
9%
Engineered Tissue
9%
Cell Proliferation
9%
Signal Transduction
9%
Combination Therapy
9%
Cell Survival
9%
Tyrosine-Kinase Inhibitor
9%
Tumor Xenograft
9%
Phosphatase
9%
Tensin
9%
Pharmacology, Toxicology and Pharmaceutical Science
Gelatin
100%
Hyaluronic Acid
100%
Glioblastoma
100%
Erlotinib
100%
Epidermal Growth Factor Receptor
45%
Neoplasm
36%
Tumor Microenvironment
18%
Combination Therapy
9%
Protein Tyrosine Kinase Inhibitor
9%
Phosphatase
9%
Tensin
9%
Biochemistry, Genetics and Molecular Biology
Restylane
100%
Hyaluronan
100%
Erlotinib
100%
Epidermal Growth Factor Receptor
83%
Signal Transduction
16%
Cell Migration
16%
Cell Proliferation
16%
Cell Survival
16%
Phosphatase
16%
Tyrosine Kinase Inhibitor
16%
STAT3
16%
CD44
16%
Tensin
16%